Logo image of DYN

DYNE THERAPEUTICS INC (DYN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DYN - US26818M1080 - Common Stock

20.64 USD
-0.14 (-0.67%)
Last: 12/23/2025, 12:16:49 PM
Fundamental Rating

2

Overall DYN gets a fundamental rating of 2 out of 10. We evaluated DYN against 530 industry peers in the Biotechnology industry. The financial health of DYN is average, but there are quite some concerns on its profitability. DYN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DYN has reported negative net income.
In the past year DYN has reported a negative cash flow from operations.
DYN had negative earnings in each of the past 5 years.
DYN had a negative operating cash flow in each of the past 5 years.
DYN Yearly Net Income VS EBIT VS OCF VS FCFDYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -48.88%, DYN perfoms like the industry average, outperforming 50.94% of the companies in the same industry.
DYN has a Return On Equity of -61.26%. This is in the better half of the industry: DYN outperforms 60.57% of its industry peers.
Industry RankSector Rank
ROA -48.88%
ROE -61.26%
ROIC N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
DYN Yearly ROA, ROE, ROICDYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DYN Yearly Profit, Operating, Gross MarginsDYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

DYN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DYN has been increased compared to 5 years ago.
There is no outstanding debt for DYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DYN Yearly Shares OutstandingDYN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DYN Yearly Total Debt VS Total AssetsDYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 7.41 indicates that DYN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.41, DYN is in the better half of the industry, outperforming 77.55% of the companies in the same industry.
A Debt/Equity ratio of 0.14 indicates that DYN is not too dependend on debt financing.
The Debt to Equity ratio of DYN (0.14) is worse than 65.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 7.41
ROIC/WACCN/A
WACCN/A
DYN Yearly LT Debt VS Equity VS FCFDYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 13.47 indicates that DYN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.47, DYN belongs to the top of the industry, outperforming 89.62% of the companies in the same industry.
A Quick Ratio of 13.47 indicates that DYN has no problem at all paying its short term obligations.
DYN has a better Quick ratio (13.47) than 89.81% of its industry peers.
Industry RankSector Rank
Current Ratio 13.47
Quick Ratio 13.47
DYN Yearly Current Assets VS Current LiabilitesDYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

DYN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.81%.
EPS 1Y (TTM)-2.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DYN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.69% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.87%
EPS Next 2Y-0.73%
EPS Next 3Y3.91%
EPS Next 5Y16.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DYN Yearly Revenue VS EstimatesDYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
DYN Yearly EPS VS EstimatesDYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYN Price Earnings VS Forward Price EarningsDYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYN Per share dataDYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.73%
EPS Next 3Y3.91%

More info and screens

0

5. Dividend

5.1 Amount

DYN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

DYNE THERAPEUTICS INC

NASDAQ:DYN (12/23/2025, 12:16:49 PM)

20.64

-0.14 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners107.19%
Inst Owner Change10.31%
Ins Owners0.26%
Ins Owner Change0.27%
Market Cap2.95B
Revenue(TTM)N/A
Net Income(TTM)-423.80M
Analysts82
Price Target35.51 (72.04%)
Short Float %12.8%
Short Ratio5.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.77%
Min EPS beat(2)-0.6%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)0.16%
Min EPS beat(4)-18.24%
Max EPS beat(4)10.13%
EPS beat(8)3
Avg EPS beat(8)-5.92%
EPS beat(12)4
Avg EPS beat(12)-7.06%
EPS beat(16)6
Avg EPS beat(16)-4.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.82%
PT rev (3m)-3.66%
EPS NQ rev (1m)3.62%
EPS NQ rev (3m)-8.02%
EPS NY rev (1m)2.32%
EPS NY rev (3m)2.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.26
P/tB 4.26
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-3.4
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS0
BVpS4.84
TBVpS4.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.88%
ROE -61.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.24%
ROA(5y)-59.12%
ROE(3y)-125.15%
ROE(5y)-86.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1076.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.47
Quick Ratio 13.47
Altman-Z 7.41
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.78%
Cap/Depr(5y)173.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.83%
EPS Next Y-7.87%
EPS Next 2Y-0.73%
EPS Next 3Y3.91%
EPS Next 5Y16.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.99%
EBIT Next 3Y-9.82%
EBIT Next 5YN/A
FCF growth 1Y-116.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.04%
OCF growth 3YN/A
OCF growth 5YN/A

DYNE THERAPEUTICS INC / DYN FAQ

Can you provide the ChartMill fundamental rating for DYNE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to DYN.


What is the valuation status of DYNE THERAPEUTICS INC (DYN) stock?

ChartMill assigns a valuation rating of 0 / 10 to DYNE THERAPEUTICS INC (DYN). This can be considered as Overvalued.


What is the profitability of DYN stock?

DYNE THERAPEUTICS INC (DYN) has a profitability rating of 1 / 10.


Can you provide the financial health for DYN stock?

The financial health rating of DYNE THERAPEUTICS INC (DYN) is 5 / 10.


What is the earnings growth outlook for DYNE THERAPEUTICS INC?

The Earnings per Share (EPS) of DYNE THERAPEUTICS INC (DYN) is expected to decline by -7.87% in the next year.